Feed FOLD
FO

Amicus Therapeutics FOLD NASDAQ · Healthcare · United States

$14.49 +0.00% +$0.00

Market cap
$4.55B
Enterprise value
$4.78B
P/E
-
Forward P/E
-
PEG
-
P/S
7.2x
P/FCF
469.5x
EV/EBITDA
112.7x
ROIC
-645.7%
Gross margin
88.5%
Net margin
-4.3%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
5.4x
Beta
0.48
Free float
99.2%

About the company

Amicus Therapeutics, Inc. is an American biotechnology company specializing in the development of innovative therapies for the treatment of rare genetic diseases, particularly lysosomal storage disorders. The company focuses on developing enzyme replacement therapies and other biologic treatments that can improve the health of patients suffering from diseases such as Fabry disease, Gaucher disease, and Pompe disease. Amicus Therapeutics is known for its advanced research in enzyme therapy and highly targeted treatment methods, offering new possibilities for patients for whom current treatments have been insufficiently effective.

Sector

Healthcare

Industry

Biotechnology

CEO

Bradley L. Campbell

Employees

499

Headquarters

Philadelphia

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Revenue grew by 15% a year over the last 3 years.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What to watch: The company made a loss over the last 12 months.

Financial health

Can it carry its debt?

  • What to watch: Operating profit does not even cover the interest on its debt.
  • What to watch: It passes only 3 of the 9 points of the Piotroski financial health test.

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

  • What speaks for it: The price moves less than the market (beta 0.48).

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy